Clinical trials
catalyst calendar across sponsors →Studies where AARD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 with posted results
Held by 8 tracked-famous managers (CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +3 more) · FINRA short interest 4.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective TrialNCT06828861Change in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Due to operational and regulatory considerations. | Drug: Placebo, ARD-101 | Hyperphagia, Prader-Willi Syndrome | 68 | 2026-05-07actual | 2026-06-30 |
| The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) TrialNCT07197034Change in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) ScoreOpen-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Due to operational and regulatory considerations. | Drug: ARD-101 | Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome | 19 | 2026-04-15actual | 2026-06-30 |
| A Study to Evaluate ARD-501 in Patients With Autism Spectrum DisorderNCT06126653Assessment of the incidence of Treatment-Emergent Adverse Events (TEAE)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Low Dose ARD-501, High Dose ARD-501, Placebo | Autism Spectrum Disorder | 5 | 2025-01-13actual | 2025-05-09 |
| A Study of Oral ARD-101 in Patients With Prader-Willi SyndromeNCT05153434Incidence of Treatment-Emergent Adverse Events (TEAE)Open-label · Treatment | Phase 2 | Completed | Drug: ARD-101 | Prader-Willi Syndrome | 19 | 2024-09-24actual | 2025-05-09 |
| Study to Evaluate ARD-101 in Adults Receiving Bariatric SurgeryNCT05215847results2024-11-14Relative Change in Body Weight (%)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ARD-101 | Bariatric Surgery, Obesity, Weight Gain | 12 | 2023-02-03actual | 2025-02-11 |
| Study to Evaluate ARD-101 in Adults With ObesityNCT05121441results2025-01-22Relative Change in Body Weight (%)Randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ARD-101, Placebo | Obesity | 20 | 2022-11-09actual | 2025-01-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19